Document:

EX-10.1

 Exhibit 10.1 

AGREEMENT 
 This Agreement
(“Agreement”) is made by and between Vaughan Clift, M.D. (“Employee”) and Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”) (collectively referred to as the “Parties” or individually referred
to as a “Party”) as of the Effective Date (as defined below). 
 RECITALS 

WHEREAS, Employee is employed by the Company; 

WHEREAS, Employee and the Company have been parties to an Employment Agreement effective as of August 1, 2010, as amended on
October 1, 2010, May 26, 2011, August 11, 2014 and July 31, 2015 (collectively, the “Employment Agreements”); 

WHEREAS, Employee and the Company entered into a Proprietary Information and Inventions Agreement with an effective date of August 21,
2010 (the “Confidentiality Agreement”); 
 WHEREAS, Employee and the Company have mutually agreed that Employee’s employment
with the Company will terminate effective July 31, 2016 (the “Separation Date”); and 
 WHEREAS, the Company and Employee
have entered into the stock-related agreements set forth on Schedule 1 (collectively, the “Stock Agreements”); 
 NOW, THEREFORE,
in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows: 
 COVENANTS 

1. Recitals. The Recitals set forth above are expressly incorporated into this Agreement. 

2. Consideration. 
 a. As
consideration for this Agreement, the Company agrees to pay Employee the sum of One Hundred Twenty-Five Thousand Dollars ($125,000.00), less applicable withholding, no later than the Company’s first regular payroll date occurring at least seven
(7) days following the Effective Date (as defined below), but in no event later than March 31, 2016. 
 b. If Employee enters into and
complies with this Agreement, and as further consideration for this Agreement, Employee’s employment with the Company will end on the Separation Date. For purposes of this Agreement, the actual last day of Employee’s employment shall be
referred to as the “Separation Date” and the time period between the Effective Date and the Separation Date shall be referred to as the “Transition Period.” Unless otherwise directed by the Company, during the Transition Period
Employee shall be available to work and provide services to the Company from Employee’s home, and Employee agrees not to report to the Company’s offices or to contact or to respond to contacts from any Company employee, contractor,
consultant, customer, vendor or prospective customer or vendor regarding Company-related matters, questions or issues without written pre-approval from the Company’s Chief Scientific Officer (“CSO”) or the

  
 Page 1 

 
Company’s Chief Financial Officer (“CFO”). During the Transition Period, Employee will continue to be employed as the Company’s Chief Regulatory Affairs Officer, be required
to perform assigned responsibilities diligently and competently, focus on effectively transitioning Employee’s duties and responsibilities as directed by the CSO or the CFO, and strictly observe and adhere to all Company policies and applicable
securities laws and other legal and regulatory requirements; provided, however, that if a failure to perform duties as described above is capable of being cured, the Company may not claim Employee has breached this Agreement due to a
failure to perform the above-described duties unless such failure has continued for more than thirty (30) days following written notice from the Company of such non-performance and Employee does not cure such failure during said period. It is
further understood that, at the CSO’s or the CFO’s discretion, Employee’s time commitment to providing services to the Company may be substantially reduced. During the Transition Period, Employee will continue to receive
Employee’s current base salary at the rate of Twenty Thousand Eight Hundred Thirty-Three Dollars and Thirty-Three Cents ($20,833.33) monthly and be eligible for regular employee benefits, including continued participation in the Company’s
health and medical plans with the Company paying the employer’s portion of the premium for these plans and Employee paying the employee portion. Employee’s salary and eligibility to participate in the Company’s employee
benefit plans and programs will cease on the Separation Date in accordance with the terms and conditions of each of those benefit plans and programs. It is further agreed that in consideration for the benefits provided under this Agreement, Employee
will be a consultant to the Company from the Separation Date through February 28, 2017, providing such consulting services as may be mutually agreed by Employee and the Company’s CSO or CFO. 

c. As further consideration for this Agreement, and provided Employee enters into and fully complies with all provisions of this Agreement and
satisfies each of the Severance Conditions described below, the Company will pay Employee an additional severance payment consisting of one of the following (i) if the AP-003 PIVOT Trial is Successful (as defined below), the amount of One Hundred
Sixty-Four Thousand Eight Hundred Ninety-Seven Dollars and Eleven Cents ($164,897.11), less applicable withholding and any amounts Employee owes the Company, or (ii) if the AP-003 B PIVOT Trial is not Successful (as defined below), the amount of
Thirty-Nine Thousand Eight Hundred Ninety-Seven Dollars and Eleven Cents ($39,897.11), less applicable withholding and any amounts Employee owes the Company. In order to satisfy all of the Severance Conditions, Employee must do each of the
following: (i) enter into (and not revoke) and comply with all provisions of this Agreement and the Confidentiality Agreement; (ii) perform Employee’s job duties and otherwise fulfill his responsibilities as described in
Section 2(b) above through July 31, 2016; and (iii) sign and return the General Release attached as Exhibit A no earlier than the Separation Date and no later than twenty-one (21) days following the Separation Date. Provided all
conditions are met to trigger one or the other of the payments referenced above, the applicable payment will be made no later than the Company’s first regular payroll date occurring at least seven (7) business days following the date the
Company receives the signed General Release attached as Exhibit A, provided Employee has not revoked it, but in no event later than August 31, 2016. In no event will any such payment be made later than sixty (60) days after the Separation Date.
For purposes of this paragraph and Section 3, the AP-003 B PIVOT Trial will be considered “Successful if it meets its primary endpoint with Ampion showing a statistically significant improvement in the WOMAC A pain score as compared to the
control and David Bar-Or is awarded a bonus based on this Trial having been Successful. Employee agrees that prior to the execution of this Agreement Employee was not entitled to receive any further monetary payments or benefits from the Company,
and that the only payments and benefits that Employee is entitled to 

  
 Page 2 

 
receive from the Company in the future are those specified in this Agreement. The Company agrees that within seven (7) business days following the Effective Date of this Agreement it will
deliver to Goodwin Procter LLP or another escrow holder the sum of One Hundred Sixty-Four Thousand Eight Hundred Ninety-Seven Dollars and Eleven Cents ($164,897.11), with instructions that this sum shall be held in escrow and not returned to the
Company until the earlier of (y) August 31, 2016 or (z) when any payment is made to Employee by the Company pursuant to this Section 2.c.

3. Stock Agreements. The Parties agree that Employee holds and shall continue to hold following the date of this Agreement the
stock options as set forth on Schedule 1, subject to the terms of the Stock Agreements. No failure to perform under or breach of this Agreement by Employee shall affect or diminish any right employee may otherwise have regarding any
vested stock options. The Parties agree that (i) Employee will continue to provide services to the Company as an employee through the Separation Date, (ii) following the Separation Date Employee will cease to provide services to the Company as an
employee and (iii) Employee did not and shall not vest in any additional portion of the unvested stock options set forth on Schedule or otherwise obtain additional equity or debt interest in the Company following the date of this Agreement, except
as set forth herein. Notwithstanding, the foregoing, Employee’s stock option to purchase 170,000 shares of the Company’s common stock granted on July 31, 2015 shall continue to vest in accordance with its terms (for the avoidance of
doubt, such stock option shall vest on the date that the Ampion clinical trial is Successful (as defined in Section 2 above) and will remain exercisable until July 31, 2017. All of Employee’s vested stock options will remain outstanding
and exercisable until July 31, 2017. Employee acknowledges that, other than as specified in this Agreement, including Schedule 1, Employee has no other equity or debt interest in the Company of any kind, including but not limited to, any
interest in stock, stock options, or other form of profit participation. 
 EMPLOYEE UNDERSTANDS THAT NEITHER THIS AGREEMENT NOR THE COURSE OF
EMPLOYEE’S EMPLOYMENT WITH THE COMPANY, OR ANY OTHER SERVICE TO THE COMPANY, GIVE OR GAVE EMPLOYEE ANY RIGHT, CONTINUING OR OTHERWISE, TO THE REVENUES AND/OR PROFITS OF THE COMPANY AND/OR ANY OTHER COMPANY RELEASEE (AS DEFINED BELOW) OR ANY
OTHER INTEREST, ECONOMIC OR OTHERWISE, IN THE COMPANY AND/OR ANY OTHER COMPANY RELEASEE (AS DEFINED BELOW), EXCEPT AS MAY BE OTHERWISE PROVIDED IN THE STOCK AGREEMENTS. 

4. Benefits and PTO Usage. Except as may be otherwise provided in this Agreement, Employee agrees that Employee’s (i)
participation in all benefits and incidents of employment, including, but not limited to, the accrual of vacation or paid time off (collectively, “PTO”) or bonuses, ceased (or will cease) as of the Separation Date; and (ii) Employee’s
health insurance benefits, if any, shall cease on the last day of July 2016, subject to Employee’s right to continue Employee’s coverage under COBRA. The Parties agree that the sum of Employee’s currently accrued and unused PTO
plus all PTO he will accrue prior to the Separation Date equals two hundred seventeen (217) hours, and that Employee will use all of this accrued PTO between the Effective Date and the Separation Date on dates of his own choosing and without
submitting any forms or other paperwork documenting such use. Accordingly, it is further agreed that there will be no remaining accrued and unused PTO to be paid to Employee as of the Separation Date. 

5. Payment of Salary and Receipt of All Benefits. Employee acknowledges and represents that, other than the consideration set
forth in this Agreement, the Company has paid or 

  
 Page 3 

 
provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses,
commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee. Employee specifically represents that Employee is not due to receive any expense reimbursements or commissions or other incentive
compensation from the Company other than as set forth in this Agreement. 
 6. Release of Claims by Employee. Employee agrees
that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators,
affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Company Releasees”). Employee, on Employee’s own behalf and on
behalf of Employee’s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Company Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim,
complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Company Releasees arising from any
omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement, including, without limitation: 

a. any and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of that
relationship; 
 b. any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of
stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law, or relating to or
arising out of any agreement, employment agreement, policy, plan, understanding, promise or contract (whether express or implied, actual or alleged, written or oral, signed or unsigned, draft or final) including, but not limited to, the Employment
Agreements, other than under the Stock Agreements; 
 c. any and all claims for wrongful discharge of employment; termination in violation
of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; commission payments; promissory estoppel; negligent or intentional
infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal
injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; 
 d. any and all claims under any
federal, state, or local law (statutory or decisional), regulation, or ordinance, including without limitation any Claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Fair Labor Standards Act, the
Colorado Anti-discrimination Act, and other statutes and the common law of the state of Colorado; 
 e. any and all claims for violation of
the federal or any state constitution; 

  
 Page 4 

 f. any and all claims arising out of any other laws and regulations relating to employment or
employment discrimination; 
 g. any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or
other tax treatment of any of the proceeds received by Employee as a result of this Agreement; and 
 h. any and all claims for
attorneys’ fees and costs. 
 Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete
general release as to the matters released. This release does not extend to any obligations incurred under this Agreement, any of Employee’s rights as an equityholder under the Stock Agreements, or any rights Employee may have to
indemnification by the Company or its affiliates. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Employee’s right to file a charge with or participate in a charge by the Equal
Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company (with the understanding that any such
filing or participation does not give Employee the right to recover any monetary damages against the Company; Employee’s release of claims herein bars Employee from recovering such monetary relief from the Company). Employee represents
that Employee has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this section. 

7. Acknowledgment of Waiver of Claims under ADEA. Employee acknowledges that Employee is waiving and releasing any rights Employee may
have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Employee agrees that this waiver and release does not apply to any rights or claims that may arise under the
ADEA after the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that Employee
has been advised by this writing that: (a) Employee should consult with an attorney prior to executing this Agreement; (b) Employee has twenty-one (21) days within which to consider this Agreement; (c) Employee has seven (7) days following
Employee’s execution of this Agreement to revoke this Agreement; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing in this Agreement prevents or precludes Employee from challenging or
seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Employee signs this
Agreement and returns it to the Company in less than the 21-day period identified above, Employee hereby acknowledges that Employee has freely and voluntarily chosen to waive the time period allotted for
considering this Agreement. Employee acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the Company’s behalf that is received prior to the eighth day after
Employee signs this Agreement. The parties agree that changes, whether material or immaterial, do not restart the running of the 21-day period. 

8. No Pending or Future Lawsuits. Employee represents that Employee has no lawsuits, claims, or actions pending in Employee’s
name, or on behalf of any other person or entity, against the Company or any of the other Company Releasees. Employee also represents that Employee does not intend to bring any claims on Employee’s own behalf or on behalf of any other person or
entity against the Company or any of the other Company Releasees. 

  
 Page 5 

 9. Release of Claims by Company. The Company hereby and forever releases Employee
from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown,
suspected or unsuspected, that the Company may possess against Employee arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement. The Company agrees that the release set
forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement or claims that cannot be released as a
matter of law. The Company represents that it has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this section. 

10. Confidentiality. Employee agrees to maintain in complete confidence the existence of this Agreement, the contents and terms of this
Agreement, and the consideration for this Agreement (hereinafter collectively referred to as “Separation Information”). Except as required by law, Employee may disclose Separation Information only to Employee’s immediate family
members, the Court or an arbitrator in any proceedings to enforce the terms of this Agreement, Employee’s attorney(s), and Employee’s accountant and any professional tax advisor to the extent that they need to know the Separation
Information in order to provide advice on tax treatment or to prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. Employee agrees that Employee will not publicize, directly or indirectly, any
Separation Information. The Company agrees to maintain confidentiality regarding Separation Information except as required by law or regulation, including without limitation Securities and Exchange Commission filing and other requirements. 

11. Trade Secrets and Confidential Information/Company Property. Employee reaffirms and agrees to observe and abide by the terms of the
Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of the Company’s trade secrets and confidential and proprietary information, noncompetition, and nonsolicitation of Company employees. Employee
affirms that Employee has returned all documents and other items provided to Employee by the Company, developed or obtained by Employee in connection with Employee’s employment with the Company, provided to him by vendors or other business
partners of the Company, or otherwise belonging to the Company. 
 12. Litigation Assistance. 

a. Employee agrees that Employee will not knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or
prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Company Releasees, unless under a subpoena or other court order to do so or as related directly to the ADEA waiver in this
Agreement. Employee agrees both to immediately notify the Company upon receipt of any such subpoena or court order, and to furnish, within three (3) business days of its receipt, a copy of such subpoena or other court order. If approached
by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Company Releasees, Employee shall state no more than that Employee cannot provide
counsel or assistance. 

  
 Page 6 

 b. Employee agrees to assist and cooperate with the Company (including all of its affiliates),
and its directors, officers, employees, agents, representatives, attorneys, auditors, accountants, consultants, and experts with respect to any (i) matter relating to Employee’s employment with the Company, (ii) pending or future litigation,
arbitration, mediation, proceeding, investigation, or inquiry of any kind (collectively, “Legal Matters”), whether or not Employee is a party to such Legal Matters, and including but not limited to the existing securities class action and
derivative litigation pending against the Company and Employee; and (iii) response to, or request for information from regulatory agencies or other governmental authorities. Employee further agrees to make himself available at mutually convenient
times during and outside of regular business hours as the Company reasonably deems necessary. The Company shall not utilize this section to require Employee to make himself available to an extent that would unreasonably interfere with
Employee’s full-time employment responsibilities. Employee’s agreement herein includes, without limitation, (x) meeting or conferring with the Company and its attorney(s) to discuss or assist with all Legal Matters, audits, or
inspections, (y) appearing without the necessity of a subpoena to testify truthfully in connection with all Legal Matters in which the Company or any affiliate calls Employee as a witness, and (z) to provide truthful affidavits or
declarations. The Company shall reimburse Employee for expenses that Employee reasonably incurs in connection with providing the assistance or cooperation required under this Agreement after receipt of appropriate documentation consistent with
the Company’s business expense reimbursement policy. Employee further agrees that should an individual representing a party adverse to the Company’s interests (including, without limitation, anyone threatening any form of legal
action) contact Employee (directly or indirectly), Employee will promptly (within 48 business hours) inform (in writing) Gregory A. Gould, Chief Financial Officer of the Company, of that fact, unless prohibited from doing so under applicable law.

 13. Nondisparagement. Employee agrees not to disparage any of the Company Releasees or their business partners, which Company
Releasees, business partners, or prospective business partners are known to Employee to have such status. The Company agrees that the members of its Board of Directors and officers will not disparage Employee. For this purpose, the term
“disparage” means, with respect to any individual or entity, negative comments regarding their integrity, fairness, satisfaction of obligations, overall performance, business practices, investment decisions, business model, equityholders,
or personnel. These nondisparagement obligations shall not in any way affect anyone’s obligation to testify truthfully in any legal proceeding. 

14. No Admission of Liability. Employee understands and acknowledges that this Agreement constitutes a compromise and settlement
of any and all actual or potential disputed claims by Employee or the Company. No action taken by the Company or the Employee hereto, either previously or in connection with this Agreement, shall be deemed or construed to be (a) an admission of
the truth or falsity of any actual or potential claims or (b) an acknowledgment or admission by the Company or Employee of any fault or liability whatsoever to the other party or to any third party. 

15. Costs. The Parties shall each bear their own costs, attorneys’ fees, and other fees incurred in connection with the
preparation of this Agreement. 
 16. ARBITRATION. THE PARTIES AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS
AGREEMENT, THEIR INTERPRETATION, AND ANY OF THE MATTERS HEREIN RELEASED, SHALL BE SUBJECT TO ARBITRATION IN 

  
 Page 7 

 
ENGLEWOOD, COLORADO, BEFORE THE AMERICAN ARBITRATION ASSOCIATION (“AAA”), PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES & MEDIATION PROCEDURES (“AAA RULES”). THE ARBITRATOR
MAY GRANT INJUNCTIONS AND OTHER RELIEF IN SUCH DISPUTES. THE ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN ACCORDANCE WITH COLORADO LAW, AND THE ARBITRATOR SHALL APPLY SUBSTANTIVE AND PROCEDURAL COLORADO LAW TO ANY DISPUTE OR CLAIM,
WITHOUT REFERENCE TO ANY CONFLICT-OF-LAW PROVISIONS OF ANY JURISDICTION. TO THE EXTENT THAT THE AAA RULES CONFLICT WITH COLORADO LAW, COLORADO LAW SHALL TAKE PRECEDENCE. THE DECISION OF THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND
BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT THE PREVAILING PARTY IN ANY ARBITRATION SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE THE ARBITRATION AWARD. THE PARTIES TO THE
ARBITRATION SHALL EACH PAY AN EQUAL SHARE OF THE COSTS AND EXPENSES OF SUCH ARBITRATION, AND EACH PARTY SHALL SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES. THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE ANY DISPUTE BETWEEN
THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY. NOTWITHSTANDING THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY OTHER PROVISIONAL REMEDY) FROM ANY COURT HAVING JURISDICTION OVER THE PARTIES
AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING TO THIS AGREEMENT AND THE AGREEMENTS INCORPORATED HEREIN BY REFERENCE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED IN THIS PARAGRAPH CONFLICT WITH ANY OTHER ARBITRATION AGREEMENT
BETWEEN THE PARTIES, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT SHALL GOVERN. 
 17. Tax Consequences. 

a. The Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration
provided to Employee or made on Employee’s behalf under the terms of this Agreement. Employee agrees and understands that Employee is responsible for payment, if any, of local, state, and/or federal taxes on the payments and any other
consideration provided hereunder by the Company and any penalties or assessments thereon. Employee further agrees to indemnify and hold the Company harmless from any claims, demands, deficiencies, penalties, interest, assessments, executions,
judgments, or recoveries by any government agency against the Company for any amounts claimed due on account of (i) Employee’s failure to pay or delayed payment of federal or state taxes, or (ii) damages sustained by the Company by reason
of any such claims, including attorneys’ fees and costs. 
 b. The Parties intend that this Agreement will be administered in
accordance with Section 409A of the Internal Revenue Code of 1986 (“Section 409A”). To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so
that all payments hereunder are exempt from or comply with Section 409A. 
 18. Authority. The Company represents and warrants
that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through 

  
 Page 8 

 
it to the terms and conditions of this Agreement. Employee represents and warrants that Employee has the capacity to act on Employee’s own behalf and on behalf of all who might claim through
Employee to bind them to the terms and conditions of this Agreement. Employee warrants and represents that there are no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released
herein. 
 19. No Representations. Employee represents that Employee has had an opportunity to consult with an attorney, and has
carefully read and understands the scope and effect of the provisions of this Agreement. Employee has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement. 

20. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part
hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. 

21. Entire Agreement. This Agreement represents the entire agreement and understanding between the Company and Employee concerning the
subject matter of this Agreement and Employee’s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the
subject matter of this Agreement and Employee’s relationship with the Company, including without limitation the Employment Agreements, but with the exception of the Confidentiality Agreement and the Stock Agreements (as such may have been
modified herein). 
 22. No Oral Modification. This Agreement may only be amended in a writing signed by Employee and a duly
authorized representative of the Company. 
 23. Governing Law. This Agreement shall be governed by the laws of the State of
Colorado, without regard for choice-of-law provisions. Employee and the Company consent to personal and exclusive jurisdiction and venue in the State of Colorado, except as otherwise provided under Section 16 (Arbitration). 

24. Effective Date. Employee understands that this Agreement shall be null and void if not executed by Employee within twenty-one
(21) days following the date Employee receives it. In the event that Employee signs this Agreement within twenty-one days, then the Company has seven days after such date to countersign the Agreement and return a fully-executed version to Employee.
This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been signed by the Company and has not been revoked by either Party before that date (the “Effective Date”). 

25. Counterparts. This Agreement may be executed in counterparts and by facsimile, and each counterpart and facsimile shall have
the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. 
 26.
Voluntary Execution of Agreement. Employee understands and agrees that Employee executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of
releasing all of Employee’s claims against the Company and any of the other Company Releasees. Employee acknowledges that: 
  

	 	(a)	Employee has read this Agreement; 

  
 Page 9 

	 	(b)	Employee has been provided the opportunity to be represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Employee’s own choice; 

 

	 	(c)	Employee understands the terms and consequences of this Agreement and of the releases it contains; and 

  

	 	(d)	Employee is fully aware of the legal and binding effect of this Agreement. 

 IN WITNESS WHEREOF, the Parties
have executed this Agreement on the respective dates set forth below. 
  

					
		 	VAUGHAN CLIFT, M.D., an individual
		
	Dated: March 1, 2016	 	 /s/ Vaughan Clift

		 	Vaughan Clift, M.D.
		
		 	AMPIO PHARMACEUTICALS, INC.
			
	Dated: March 2, 2016	 	By	 	 /s/ Michael Macaluso

		 		 	Michael Macaluso
		 		 	Chief Executive Officer

  
 Page 10 

 Schedule 1 

Stock-Related Agreements between Ampio Pharmaceuticals, Inc. and Vaughan Clift, M.D. 

 

													
	 	  	 Agreement
	  	 Date of Grant
	  	 No. of

Shares/Class of
 Stock
	  	 Vested as of the
Date of this

Agreement
	  	 Unvested as

of the Date
 of this

Agreement
	  	 Accelerated

on
 Termination

Date

	 #1
	  	Incentive Stock Option	  	8/12/2010	  	365,000 shares of Common Stock	  	In full	  	None	  	None
	 #2
	  	Incentive Stock Option	  	5/7/2012	  	150,000 shares of Common Stock	  	In full	  	None	  	None
	 #3
	  	Incentive Stock Option	  	7/15/2013	  	170,000 shares of Common Stock	  	In full	  	None	  	None
	 #4
	  	Incentive Stock Option	  	8/11/2014	  	170,000 shares of Common Stock	  	In full	  	None	  	None
	 #5
	  	Incentive Stock Option	  	7/31/2015	  	170,000 shares of Common Stock	  	None	  	170,000	  	None

  
 Page 11 

 EXHIBIT A 

GENERAL RELEASE 

  
 Page 12 

 GENERAL RELEASE 

Background 
 Vaughan Clift, M.D.
(“Employee”) acknowledges that in connection with the ending of his employment with Ampio Pharmaceuticals, Inc. (the “Company”), he entered into an Agreement dated March 1, 2016 (the “Agreement”). Employee understands
that this is the General Release referenced in the Agreement. Employee further understands that he may not sign this General Release until on or after the Separation Date (as defined in the Agreement) but that he must return it to the Company on or
before twenty-one (21) days from the Termination Date. 
 Release and Related Terms 

1. Employee acknowledges that Company has paid him all salary, vacation pay, and all other compensation through the last
through the last day of his employment. 
 2. Employee acknowledges that, except for the severance payment described in
Section 2.c. of the Agreement, he is not entitled to any other compensation or benefits from the Company. 
 3. Employee
understands that, regardless of whether he signs this General Release, the Agreement shall remain in full force and effect, except that he will not have satisfied the Severance Conditions described in Section 2.c. of the Agreement to receive the
severance payment described in Section 2.c. of the Agreement. 
 4. Employee agrees that the foregoing consideration
represents settlement in full of all outstanding obligations owed to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan
administrators, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Employee, on his own behalf and on behalf of his respective heirs, family members,
executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action
relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including
the Effective Date of this General Release, including, without limitation: 
 a. any and all claims relating to or arising from
Employee’s employment relationship with the Company and the termination of that relationship; 
 b. any and all claims relating to, or
arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate
law, and securities fraud under any state or federal law; 

  
 Page 13 

 c. any and all claims for wrongful discharge of employment; termination in violation of public
policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional
distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery;
invasion of privacy; false imprisonment; conversion; and disability benefits; 
 d. any and all claims for violation of any federal, state,
or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor
Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification
Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the Immigration Control and Reform Act; and the Colorado Anti-Discrimination Act; 

e. any and all claims for violation of the federal or any state constitution; 

f. any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; 

g. any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the
proceeds received by Employee as a result of the Agreement; and 
 h. any and all claims for attorneys’ fees and costs. 

This General Release does not release claims that cannot be released as a matter of law, including, but not limited to, Employee’s right
to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment,
against the Company (with the understanding that any such filing or participation does not give Employee the right to recover any monetary damages against the Company; Employee’s release of claims herein bars Employee from recovering such
monetary relief from the Company). Employee represents that he has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this General Release.

 Employee represents that he has no lawsuits, claims, or actions pending in his name, or on behalf of any other person or entity, against
the Company or any of the other Releasees. Employee also represents that he does not intend to bring any claims on his own behalf or on behalf of any other person or entity against the Company or any of the other Releasees. 

Employee acknowledges that he is waiving and releasing any rights he may have under the Age Discrimination in Employment Act of 1967
(“ADEA”), and that this waiver and 

  
 Page 14 

 
release is knowing and voluntary. Employee agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this
Agreement. Employee acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that he has been advised by this writing
that: (a) he should consult with an attorney prior to executing this Agreement; (b) he has had twenty-one (21) days to consider this General Release; (c) he has seven (7) days following his execution of this General Release to revoke it; (d)
this General Release shall not be effective until after the revocation period has expired; and (e) nothing in this General Release prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this
waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. Employee acknowledges and understands that revocation must be accomplished by a written notification
to the Company’s Chief Executive Officer that is received prior to the eighth day after Employee signs this Agreement. The parties agree that changes, whether material or immaterial, do not restart the running of the 21-day period. 

This General Release shall become effective on the eighth day after Employee returns a signed copy of the General Release to the Company.

EMPLOYEE ACKNOWLEDGES THAT HE HAS READ THIS GENERAL RELEASE THOROUGHLY, UNDERSTANDS ITS TERMS AND HAS SIGNED IT KNOWINGLY AND VOLUNTARILY. EMPLOYEE
UNDERSTANDS THAT THIS GENERAL RELEASE IS A LEGAL DOCUMENT. EMPLOYEE ACKNOWLEDGES THAT HE HAS BEEN ADVISED BY THE COMPANY TO DISCUSS ALL ASPECTS OF THIS GENERAL RELEASE WITH HIS ATTORNEY. 

 

			
	Dated: March 1, 2016	 	 /s/ Vaughan Clift

		 	Vaughan Clift, M.D.

  
 Page 15Exhibit

Exhibit 10.1

SPX FLOW
SPX FLOW STOCK COMPENSATION PLAN
RESTRICTED STOCK AGREEMENT
AWARD FOR NON-EMPLOYEE DIRECTORS
THIS AGREEMENT (the “Agreement”) is made between SPX FLOW, Inc., a Delaware corporation (the “Company”), and the Recipient pursuant to the SPX FLOW Stock Compensation Plan, as amended from time to time, and related plan documents (the “Plan”) in combination with an SPX FLOW Restricted Stock Summary (the “Award Summary”) to be displayed at the Fidelity website.  The Award Summary, which identifies the person to whom the shares of Restricted Stock are granted (the “Recipient”) and specifies the date (the “Award Date”) and other details of this grant of Restricted Stock, and the electronic acceptance of this Agreement (which also is to be displayed at the Fidelity website), are incorporated herein by reference.  Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Plan.  The parties hereto agree as follows:
1.Grant of Restricted Stock.  The Company hereby grants to the Recipient the number of shares of Restricted Stock specified in the Award Summary (the “Award”), subject to the terms and conditions of the Plan and this Agreement.  Each share of Restricted Stock will entitle the Recipient to a share of Common Stock when the share of Restricted Stock ceases to be subject to a Period of Restriction (as specified in Section 4 below).  The Recipient must accept the Restricted Stock Award within [____] days after notification that the Award is available for acceptance and in accordance with the instructions provided by the Company.  The Award automatically will be rescinded upon the action of the Company, in its discretion, if the Award is not accepted within [____] days after notification is sent to the Recipient indicating availability for acceptance.  No payment of cash is required for the award of the Restricted Stock pursuant to this Agreement.  
2.Restrictions.  The Restricted Stock evidenced by this Award may not be sold, transferred, pledged, assigned, used to exercise options or otherwise alienated or hypothecated, whether voluntarily or involuntarily or by operation of law, until the Restricted Stock ceases to be subject to any applicable Period of Restriction specified in Section 4 below or as otherwise provided in the Plan or this Agreement.  Except for such restrictions, and the provisions relating to dividends paid during the Period of Restriction as described in Section 9, the Recipient will be treated as the owner of the shares of Restricted Stock and shall have all of the rights of a shareholder, including, but not limited to, the right to vote such shares.  
3.Restricted Stock Certificates.  The Award may be evidenced in such manner as the Board (or applicable committee thereof) shall determine.  The stock certificate(s) representing the Restricted Stock may be issued or held in book entry form promptly following the acceptance of this Agreement.  If a stock certificate is issued, it shall be delivered to the Secretary of the Company or such other custodian as may be designated by the Company, to be held until the applicable Period of Restriction ends or until the Restricted Stock is forfeited.  The certificates representing shares of Restricted Stock granted pursuant to this Agreement, if issued, shall bear a legend in substantially the form set forth below:
The sale or other transfer of the shares of stock represented by this certificate, whether voluntary, involuntary or by operation of law, is subject to certain restrictions on transfer set forth in the SPX FLOW Stock Compensation Plan, as adopted effective September 23, 2015, and as further amended from time to time, rules and administration adopted pursuant to such Plan, and a Restricted Stock award agreement with an Award Date as specified in the Recipient’s Award Summary.  A copy of the Plan, such rules and such Restricted Stock award agreement may be obtained from the Secretary of SPX FLOW, Inc.
4.Period of Restriction.  Subject to the provisions of the Plan and this Agreement, unless vested or forfeited earlier as described in Section 5, 6, or 7 of this Agreement, as applicable, the number of shares of Restricted Stock awarded hereunder shall cease being subject to a Period of Restriction and become vested and freely transferable at the close of business on the day before the date of the Company’s next regular annual meeting of shareholders held after the grant of this Award, if the Non-Employee Director remains a member of the Board through that time.
Upon vesting, all vested shares cease to be considered Restricted Stock, subject to the terms and conditions of the Plan and this Agreement, and the Recipient shall be entitled to have the legend removed from his or her Common Stock certificate(s), if applicable.  

5.Vesting upon Disability or Death.  If, while any shares of Restricted Stock are subject to any applicable Period of Restriction, the Recipient experiences a termination of Service by reason of Disability (as defined below) or death, such shares of Restricted Stock shall become fully vested and shall cease to be subject to any Period of Restriction as of the date of such termination of Service.  “Disability” means, in the written opinion of a qualified physician selected by the Board (or applicable committee thereof), the Recipient is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months unable to perform the functions of a member of the Board.   
6.Forfeiture upon Termination due to Reason other than Disability or Death.  If, while any shares of Restricted Stock are subject to any applicable Period of Restriction, the Recipient experiences a termination of Service for any reason other than the Recipient’s Disability or death, then the Recipient shall forfeit any such shares of Restricted Stock on the date of such termination of Service.
7.Termination Without Cause Following Change of Control.  In the event the Recipient’s Service is terminated without Cause within two years following a “Change of Control” of the Company as defined in this Section, then any shares of outstanding Restricted Stock shall become fully vested as of the termination without Cause and shall cease to be subject to any applicable Period of Restriction.  A “Change of Control” shall be deemed to have occurred if:
(a)Any “Person” (as defined below), excluding for this purpose (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company, and (iii) any entity organized, appointed or established for or pursuant to the terms of any such plan that acquires beneficial ownership of Common Stock, is or becomes the “Beneficial Owner” (as defined below) of twenty-five percent (25%) or more of the Common Stock then outstanding; provided, however, that no Change of Control shall be deemed to have occurred as the result of an acquisition of Common Stock by the Company which, by reducing the number of shares outstanding, increases the proportionate beneficial ownership interest of any Person to twenty-five percent (25%) or more of the Common Stock then outstanding, but any subsequent increase in the beneficial ownership interest of such a Person in Common Stock shall be deemed a Change of Control; and provided further that if the Board determines in good faith that a Person who has become the Beneficial Owner of Common Stock representing twenty-five percent (25%) or more of the Common Stock then outstanding has inadvertently reached that level of ownership interest, and if such Person divests as promptly as practicable a sufficient number of shares of the Company so that the Person no longer has a beneficial ownership interest in twenty-five percent (25%) or more of the Common Stock then outstanding, then no Change of Control shall be deemed to have occurred.  For purposes of this paragraph (a), the following terms shall have the meanings set forth below:
(i)“Person” shall mean any individual, firm, limited liability company, corporation or other entity, and shall include any successor (by merger or otherwise) of any such entity.
(ii)“Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
(iii)A Person shall be deemed the “Beneficial Owner” of and shall be deemed to “beneficially own” any securities:
(A)which such Person or any of such Person’s Affiliates or Associates beneficially owns, directly or indirectly (determined as provided in Rule 13d-3 under the Exchange Act);

(B)which such Person or any of such Person’s Affiliates or Associates has (1) the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities), or upon the exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person’s Affiliates or Associates until such tendered securities are accepted for purchase or exchange; or (2) the right to vote pursuant to any agreement, arrangement or understanding; provided, however, that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or understanding to vote such security (a) arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the Exchange Act and (b) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor report); or
(C)which are beneficially owned, directly or indirectly, by any other Person with which such Person or any of such Person’s Affiliates or Associates has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting (except to the extent contemplated by the proviso to subparagraph (a)(iii)(B)(2), above) or disposing of any securities of the Company.
Notwithstanding anything in this “Beneficial Ownership” definition to the contrary, the phrase “then outstanding,” when used with reference to a Person’s beneficial ownership of securities of the Company, shall mean the number of such securities then issued and outstanding together with the number of such securities not then actually issued and outstanding which such Person would be deemed to own beneficially hereunder.
(b)During any period of two (2) consecutive years (not including any period prior to the acceptance of this Agreement), individuals who at the beginning of such two-year period constitute the Board and any new director or directors (except for any director designated by a person who has entered into an agreement with the Company to effect a transaction described in paragraph (a), above, or paragraph (c), below) whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; or
(c)The consummation of: (i) a plan of complete liquidation of the Company, (ii) an agreement for the sale or disposition of the Company or all or substantially all of the Company’s assets, (iii) a plan of merger or consolidation of the Company with any other corporation, or (iv) a similar transaction or series of transactions involving the Company (any transaction described in parts (i) through (iv) of this paragraph (c) being referred to as a “Business Combination”), in each case unless after such a Business Combination the shareholders of the Company immediately prior to the Business Combination continue to own at least seventy-five percent (75%) of the voting securities of the new (or continued) entity immediately after such Business Combination, in substantially the same proportion as their ownership of the Company immediately prior to such Business Combination.  
Notwithstanding any provision of this Agreement to the contrary, a “Change of Control” shall not include any transaction described in paragraph (a) or (c), above, where, in connection with such transaction, the Recipient and/or any party acting in concert with the Recipient substantially increases his or its, as the case may be, ownership interest in the Company or a successor to the Company (other than through conversion of prior ownership interests in the Company and/or through equity awards received entirely as compensation for past or future personal services).  

8.Effect of Change of Control.  In the event of a Change of Control as defined in Section 7 of this Agreement: 
(a)No cancellation, termination, lapse of Period of Restriction, settlement or other payment shall occur with respect to any Restricted Stock if the Board (or applicable committee thereof) (as constituted immediately prior to the Change in Control) reasonably determines, in good faith, prior to the Change in Control that the Restricted Stock shall be honored or assumed or new rights substituted therefor by an Alternative Award, in accordance with the terms of Section 14.5 of the Plan.  
(b)Notwithstanding Section 8(a), if an Alternative Award meeting the requirements of Section 14.5 of the Plan cannot be issued, or the Board (or applicable committee thereof) so determines at any time prior to the Change of Control, any Restricted Stock subject to an applicable Period of Restriction shall become fully vested and free of any Period of Restriction immediately prior to the Change of Control.
9.Dividends Paid During Period of Restriction.  If cash dividends are paid with respect to any shares of Restricted Stock, such dividends shall be deposited in the Recipient’s name in an escrow or similar account maintained by the Company for this purpose.  Such dividends shall, except as noted below, be subject to the same Period of Restriction as the shares of Restricted Stock to which they relate.  The dividends shall be paid to the Recipient in cash (subject to all applicable tax withholding), without adjustment for interest, as soon as administratively practicable after the date the related shares of Restricted Stock cease to be subject to any Period of Restriction (or, if earlier, the date the related shares of Restricted Stock cease to be subject to a substantial risk of forfeiture).  If the related shares of Restricted Stock are forfeited, then any dividends related to such shares shall also be forfeited on the same date.  If any dividends on Restricted Stock are paid in shares of Common Stock, and subject to other applicable provisions of the Plan and this Agreement, the dividend shares shall be subject to the same restrictions as the shares of Restricted Stock with respect to which they were paid, and shall vest or be forfeited in the same manner as the underlying Restricted Stock.
10.Adjustment in Capitalization.  In the event of any change in the Common Stock of the Company through stock dividends or stock splits, a corporate spin-off, reverse spin-off, split-off or split-up, or recapitalization, merger, consolidation, exchange of shares, or a similar event, the number of shares of Restricted Stock subject to this Agreement shall be equitably adjusted by the Board (or applicable committee thereof) to preserve the intrinsic value of any Awards granted under the Plan.  Such mandatory adjustment may include a change in any or all of the number and kind of shares of Common Stock or other equity interests underlying the Restricted Stock, and/or if reasonably determined in good faith by the Board (or applicable committee thereof) prior to such adjustment event, that the Restricted Stock (in whole or in part) shall be replaced by Alternative Awards meeting the requirements set forth in Section 14.5 of the Plan.  In addition, the Board (or applicable committee thereof) may make provisions for a cash payment to the Recipient in such event.  The number of shares of Common Stock or other equity interests underlying the Restricted Stock shall be rounded to the nearest whole number.  Any such adjustment shall be consistent with Code Section 162(m) to the extent the Award is subject to such section of the Code and shall not result in adverse tax consequences to the Recipient under Code Section 409A.
11.Delivery of Stock Certificates.  Subject to the requirements of Sections 12 and 13 below, as promptly as practicable after the shares of Restricted Stock cease to be subject to the applicable Period of Restriction in accordance with this Agreement, the Company may, if applicable, cause to be issued and delivered to the Recipient, the Recipient’s legal representative, or a brokerage account for the benefit of the Recipient, as the case may be, certificates for the shares of Common Stock that correspond to the vested shares of Restricted Stock, or, pursuant to Section 8, a check will be delivered to the last known address of the Recipient. 
12.Tax Withholding.  Regardless of any action the Company or any Subsidiary of the Company takes with respect to any or all income tax, social security, payroll tax, payment on account or other tax-related withholding (“Tax”) that the Recipient is required to bear pursuant to all applicable laws, the Recipient hereby acknowledges and agrees that the ultimate liability for all Tax is and remains the responsibility of the Recipient.
The Company advises the Recipient to consult a lawyer or accountant with respect to the tax consequences for the Recipient under the Plan.
The Company and/or any Subsidiary of the Company: (a) make no representations or undertakings regarding the tax treatment in connection with the Plan; and (b) do not commit to structure the Plan to reduce or eliminate the Recipient’s liability for Tax.
13.Securities Laws.  This Award is a private offer that may be accepted only by the Recipient who is a director of the Company or a Subsidiary of the Company and who satisfies the eligibility requirements outlined in the Plan and the Board’s (or applicable committee’s) administrative procedures.  If a registration statement under the Securities Act of 1933, as amended, is not in effect with respect to the shares of Common Stock to be issued pursuant to this Agreement, the Recipient hereby represents 

that the Recipient is acquiring the shares of Common Stock for investment and with no present intention of selling or transferring them and that the Recipient will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Common Stock may then be listed.
14.Exemption from Code Section 409A.  Notwithstanding any provision of the Plan or this Agreement to the contrary, the Award is intended to be exempt from Code Section 409A and the interpretive guidance thereunder.  The Plan and the Agreement will be construed and interpreted in accordance with such intent.  References in the Plan and this Agreement to “termination of Service” and similar terms shall mean a “separation from service” within the meaning of that term under Code Section 409A.  
15.No Legal Rights.  Participation in the Plan is permitted only on the basis that the Recipient accepts all of the terms and conditions of the Plan and this Agreement, as well as the administrative rules established by the Board (or applicable committee thereof).  This Agreement shall not confer upon the Recipient any right to continue to provide Services.  Neither the Plan nor this Agreement confers on the Recipient any legal or equitable rights (other than those related to the Restricted Stock Award) against the Company or any Subsidiary or directly or indirectly gives rise to any cause of action in law or in equity against the Company or any Subsidiary.
16.No Fractional Shares.  No fractional shares of Common Stock shall be issued or delivered under this Agreement.  The Board (or applicable committee thereof) shall determine whether cash or other property shall be issued or paid in lieu of such fractional shares of Common Stock or whether such fractional shares of Common Stock or any rights thereto shall be forfeited or otherwise eliminated.
17.Plan Terms and Board Authority.  This Agreement and the rights of the Recipient hereunder are subject to all of the terms and conditions of the Plan, as it may be amended from time to time, as well as to such rules and regulations as the Board (or applicable committee thereof) may adopt for administration of the Plan.  It is expressly understood that the Board (or applicable committee thereof) is authorized to administer, construe and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, all of which shall be binding upon the Recipient.  Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.  The Recipient hereby acknowledges receipt of a copy of the Plan and this Agreement.
18.Amendment.  The Board (or applicable committee thereof) may at any time amend, modify or terminate the Plan and this Agreement; provided, however, that no such action of the Board (or applicable committee thereof) shall adversely affect the Recipient’s rights under this Agreement without the consent of the Recipient.  The Board (or applicable committee thereof) to the extent it deems necessary or advisable in its sole discretion, reserves the right, but shall not be required, to unilaterally amend or modify this Agreement so that the Award qualifies for exemption from or complies with Code Section 409A; provided, however, that the Board (or applicable committee thereof) and the Company make no representations that the Award shall be exempt from or comply with Code Section 409A and make no undertaking to preclude Code Section 409A from applying to the Award.
19.Severability.  If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any jurisdiction, or as to any person, or would disqualify the Plan or the Agreement under any law deemed applicable by the Board (or applicable committee thereof), such provision shall be construed or deemed amended to conform to applicable laws, or, if it cannot be so construed or deemed amended without, in the Board’s (or applicable committee’s) determination, materially altering the intent of the Plan or the Agreement, such provision shall be stricken as to such jurisdiction or person, and the remainder of the Agreement shall remain in full force and effect.
20.Governing Law and Jurisdiction.  The Plan and this Agreement shall be construed in accordance with and governed by the laws of the State of Delaware, United States of America.  The jurisdiction and venue for any disputes arising under, or any action brought to enforce (or otherwise relating to), the Plan will be exclusively in the courts in the State of North Carolina, County of Mecklenburg, United States of America, including the Federal Courts located therein (should Federal jurisdiction exist).  As consideration for and by accepting the Award, the Recipient agrees that the Governing Law and Jurisdiction provisions of this Section 20 shall supersede any Governing Law or similar provisions contained or referenced in any prior equity awards made by the Company to the Recipient, and, accordingly, such prior equity awards shall become subject to the terms and conditions of the Governing Law and Jurisdiction provisions of this Section 20.
21.Successors.  All obligations of the Company under this Agreement will be binding on any successor to the Company, whether the existence of the successor results from a direct or indirect purchase of all or substantially all of the business or assets of the Company or both, or a merger, spin-off, consolidation or otherwise.

22.Compensation Recovery.  This Award shall be subject to any compensation recovery policy adopted by the Company, including any policy required to comply with applicable law or listing standards, as such policy may be amended from time to time in the sole discretion of the Company.  As consideration for and by accepting the Award, the Recipient agrees that all prior equity awards made by the Company to the Recipient shall become subject to the terms and conditions of the provisions of this Section 22.
23.Data Privacy.  The Recipient agrees that the Company, with its headquarters located at 13320 Ballantyne Corporate Place, Charlotte, North Carolina, USA 28277, is the data controller in the context of the Plan.  To the extent applicable, the Recipient agrees that this Section 23 shall apply to data as described below.  
The Recipient hereby explicitly and unambiguously consents to the collection, storage, use, processing and transfer, in electronic or other form, of the Recipient’s personal data as described below by and among, as applicable, the Recipient’s employer and any of its affiliates for the exclusive purpose of implementing, administering and managing the Recipient’s participation in the Plan, and the transfer of such data by them to government and other regulatory authorities for the purpose of complying with their legal obligations in connection with the Plan.
The Recipient understands that the Recipient’s employer and any of its affiliates may hold certain personal information about him or her, including the Recipient’s name, date of birth, date of hire, home and business addresses and telephone numbers, e-mail address, business group/segment, employment status, account identification, and details of all rights and other entitlement to shares awarded, cancelled, purchased, vested, unvested or outstanding in the Recipient’s favor pursuant to this Agreement, for the purpose of managing and administering the Plan (“Data”).
The Recipient further agrees that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Recipient’s country or elsewhere, including outside the European Economic Area, and that the Recipient’s country may have less adequate data privacy laws and protections than the Recipient’s country.  The Company has entered into contractual arrangements to ensure the same safeguards for data as required under European Union Law.  A third party to whom the information may be passed is Fidelity Investments and its affiliates.  The Recipient understands that the Recipient may request a list with the names and addresses of any potential recipients of the Data by contacting the Recipient’s local human resources representative.  The Recipient authorizes recipients of the Data to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Recipient’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom shares acquired pursuant to the Plan may be deposited.
The Recipient understands that Data will be held only as long as necessary to implement, administer and manage the Recipient’s participation in the Plan.  The Recipient understands that the Recipient may, at any time, view the Recipient’s Data, request additional information about the storage and processing of Data, require any necessary amendments to the Recipient’s Data or refuse or withdraw the consents herein, in any case without cost, by contacting the Company’s local data privacy administrator.
The Recipient understands, however, that refusing or withdrawing the Recipient’s consent, or that refusing to disclose the Data, although it will not have any negative effect on the Recipient’s employment, may affect the Recipient’s ability to participate in the Plan.  For more information on the consequences of the Recipient’s refusal to consent or withdrawal of consent, or refusal to disclose the Data, the Recipient understands that the Recipient may contact the Company’s local data privacy administrator.
24.Further Assurances.  The Recipient agrees to use his or her reasonable efforts to proceed promptly with the transactions contemplated herein, to fulfill the conditions precedent for the Recipient’s benefit or to cause the same to be fulfilled and to execute such further documents and other papers and perform such further acts as may be reasonably required or desirable to carry out the provisions hereof and the transactions contemplated herein.
25.Addendums.  The Company may adopt addendums to this Agreement, which shall constitute part of this Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]